GSK Signs $43M Artificial Intelligence-Driven Drug Development Deal

Jul 04, 2017

GlaxoSmithKline is putting potentially $43 million into Scottish artificial intelligence (AI) company Exscientia, which aims to use deep learning to develop new drugs. If pre-clinical milestones are met, GSK will make payments along with its research funding.

According to Exscientia, it will be able to find potential treatments in quarter time and cost.

GSK will be offering up data along with a series of 10 disease-related targets. Exscientia will then leverage its supercomputers to simulate the trial process. 

This deal comes as other pharma giants like Merck, J&J and Sanofi explore how it can leverage AI in its discovery process.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments